ELOVL1 and neoplasm: Considering that we manipulated antigen-specific T cells (OT-I and Pmel-1), genetic deletion of Elovl1 could be applied to CAR T directed against solid tumour antigens, to sustain their persistence and at the same time sensitize the tumour to ICB treatment.